Editorial: anti-tumour necrosis factor antibodies - can efficacy be regained?

被引：1

作者：

Bar-Yoseph, H. ^{[1
]}

Chowers, Y. ^{[1
]}

机构：

[1] Rambam Hlth Care Campus, Gastroenterol Inst, Haifa, Israel

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2017年 / 45卷 / 11期

关键词：

INFLAMMATORY-BOWEL-DISEASE; INFLIXIMAB; IMMUNOMODULATOR; THIOPURINES; THERAPY;

D O I：

10.1111/apt.14047

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1473 / 1474

页数：2

共 12 条

[1] Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy
Baert, Filip
Drobne, David
Gils, Ann
Vande Casteele, Niels
Hauenstein, Scott
Singh, Sharat
Lockton, Steve
Rutgeerts, Paul
Vermeire, Severine
[J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (09) : 1474 - U352
[2] Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines
Bar-Yoseph, Haggai
Waterman, Matti
Almog, Ronit
Billiet, Thomas
Vermeire, Severine
Ungar, Bella
Yanai, Henit
Dotan, Iris
Ben-Horin, Shomron
Chowers, Yehuda
[J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (01) : 69 - 75
[3] Review article: loss of response to anti-TNF treatments in Crohn's disease
Ben-Horin, S.
Chowers, Y.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (09) : 987 - 995
[4] Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines
Ben-Horin, S.
Goldstein, I.
Fudim, E.
Picard, O.
Yerushalmi, Z.
Barshack, I.
Bank, I.
Goldschmid, Y.
Bar Meir, S.
Mayer, L.
Chowers, Y.
[J]. GUT, 2009, 58 (03) : 396 - 403
[5] Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
Ben-Horin, Shomron
Waterman, Matti
Kopylov, Uri
Yavzori, Miri
Picard, Orit
Fudim, Ella
Awadie, Halim
Weiss, Batia
Chowers, Yehuda
[J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (04) : 444 - 447
[6] Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease
Chaparro, M.
Guerra, I.
Munoz-Linares, P.
Gisbert, J. P.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (09) : 971 - 986
[7] Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
Louis, Edouard
Mary, Jean-Yves
Vernier-Massouille, Gwenola
Grimaud, Jean-Charles
Bouhnik, Yoram
Laharie, David
Dupas, Jean-Louis
Pillant, Helene
Picon, Laurence
Veyrac, Michel
Flamant, Mathurin
Savoye, Guillaume
Jian, Raymond
Devos, Martine
Porcher, Raphael
Paintaud, Gilles
Piver, Eric
Colombel, Jean-Frederic
Lemann, Marc
[J]. GASTROENTEROLOGY, 2012, 142 (01) : 63 - U201
[8] Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease
Strik, A. S.
van den Brink, G. R.
Ponsioen, C.
Mathot, R.
Loewenberg, M.
D'Haens, G. R.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (08) : 1128 - 1134
[9] CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes
Tiede, I
Fritz, G
Strand, S
Poppe, D
Dvorsky, R
Strand, D
Lehr, HA
Wirtz, S
Becker, C
Atreya, R
Mudter, J
Hildner, K
Bartsch, B
Holtmann, M
Blumberg, R
Walczak, H
Iven, H
Galle, PR
Ahmadian, MR
Neurath, MF
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (08) : 1133 - 1145
[10] The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
Ungar, Bella
Chowers, Yehuda
Yavzori, Miri
Picard, Orit
Fudim, Ella
Har-Noy, Ofir
Kopylov, Uri
Eliakim, Rami
Ben-Horin, Shomron
[J]. GUT, 2014, 63 (08) : 1258 - 1264

← 1 2 →